Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 7/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25281271 | 0.98 | POLB (0.57) | POLBCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30931485 | 0.95 | POLB (0.51) | POLBLTA4HCHRNB2CHRNA4HTR6 | |
| SCHEMBL1484949 | 0.95 | POLB (0.51) | POLBLTA4HCHRNB2CHRNA4HTR6 | |
| SCHEMBL13620123 | 0.95 | POLB (0.51) | POLBLTA4HCHRNB2CHRNA4HTR6 | |
| SCHEMBL1484948 | 0.95 | POLB (0.51) | POLBLTA4HCHRNB2CHRNA4HTR6 | |
| SCHEMBL27946219 | 0.81 | HPGD (0.47) | POLBCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13801178 | 0.79 | POLB (0.49) | POLBCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4148589 | 0.79 | PSEN1 (0.43) | POLBCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL818603 | 0.77 | LTA4H (0.43) | CYP2D6LTA4HHRH3 | |
| SCHEMBL3169928 | 0.75 | POLB (0.51) | POLBCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742047-B1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-05-12 | — | — | EP | disclosed |
| US-9598407-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
| CN-105503869-A | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R & D IRELAND | 2016-04-20 | — | — | CN | disclosed |
| CN-103917540-B | Antibacterial piperidinyl-substituted 3, 4-dihydro-1H- [1, 8] naphthyridinones | JANSSEN R&D IRELAND (IE) | 2016-03-16 | — | — | CN | disclosed |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-11 | — | — | US | disclosed |
| US-9012634-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2015-04-21 | — | — | US | disclosed |
| CN-103917540-A | Antibacterial piperidinyl-substituted 3, 4-dihydro-1H- [1,8] naphthyridinones | JANSSEN R & D IRELAND | 2014-07-09 | — | — | CN | disclosed |
| EP-2742047-A1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen R&D Ireland (IE) | 2014-06-18 | — | — | EP | disclosed |
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2014-06-12 | — | — | US | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| WO-2010099938-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010067233-A1 | 1,2,4 TRIAZOLO [4, 3 -A] [1,5] BENZODIAZEPIN-5 (6H) -ONES AS AGONISTS OF THE CHOLECYSTOKININ-1 RECEPTOR (CCK-IR) | PFIZER INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | FAR1, DNASE1, LAMP1 | POLB 345/4885CYP1A2 363/4885CYP3A4 540/4885 |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | NQO2, ALPI, ECI1 | POLB 102/4885CYP1A2 210/4885CYP3A4 295/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | POLB 4435/4885CYP1A2 2489/4885CYP3A4 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.